CTA
KRTX

Carillon Tower Advisers’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Carillon Tower Advisers’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$18.7M Sell
183,606
-11,369
-6% -$1.05M 0.11% 254
2020
Q3 		$15.1M Buy
194,975
+11,369
+6% +$969K 0.2% 188
2020
Q2 		$20.5M Buy
+183,606
New +$16M 0.16% 191

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Carillon Tower Advisers's KRTX Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Karuna Therapeutics, Inc. Common Stock (KRTX) stake by 5.8% in Q4 2020, selling an estimated $1.05M and leaving 183,606 shares worth $18.7M. The position accounts for 0.11% of the portfolio, ranked #254.

Carillon Tower Advisers first reported a position in KRTX in Q2 2020 and has held it in 3 quarters since. The position peaked at $20.5M in Q2 2020. 143 funds tracked by Wall St. Rank hold KRTX as of Q4 2020.

  • Carillon Tower Advisers held 183,606 shares of Karuna Therapeutics, Inc. Common Stock worth $18.7M as of Q4 2020.
  • Carillon Tower Advisers sold 11,369 Karuna Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $1.05M.
  • Karuna Therapeutics, Inc. Common Stock made up 0.11% of Carillon Tower Advisers's portfolio in Q4 2020, its #254 holding.
  • Carillon Tower Advisers first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2020 and has held it in 3 quarters since.
  • Carillon Tower Advisers's Karuna Therapeutics, Inc. Common Stock position peaked at $20.5M in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.